Skeletal consequences of hormone therapy discontinuance: A systematic review

Obstetrical and Gynecological Survey

Volumn 61, Issue 2, 2006, Pages 115-124

  Simon, James A ^a,b,f   Wehren, Lois E ^c   Ascott Evans, Brynne H ^d   Omizo, Molly K N ^e   Silfen, Sheryl L ^c   Lombardi, Antonio ^c  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b Women's Health Research Center   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d STELLENBOSCH UNIVERSITY   (South Africa)

^e OREGON OSTEOPOROSIS CENTER   (United States)

^f NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CENTCHROMAN; CLODRONIC ACID; ESTRADIOL; ESTROGEN; HORMONE; MEDROXYPROGESTERONE ACETATE; MESTRANOL; NANDROLONE DECANOATE; NORETHISTERONE ACETATE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STEROID; TAMOXIFEN; TOREMIFENE; VITAMIN D DERIVATIVE;

BODY MASS; BONE DENSITY; EMBASE; FRACTURE; HIP; HORMONAL THERAPY; HUMAN; MEDLINE; MENOPAUSAL SYNDROME; OSTEOLYSIS; OSTEOPOROSIS; REVIEW; SPINE; TIME SERIES ANALYSIS;

AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS; SPINE;

EID: 33644845672     PISSN: 00297828     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ogx.0000189152.95070.f8     Document Type: Review

References (44)

1. Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 1996;276:1389-1396.
2. Cauley JA, Robbins J, Cummings SR, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative Randomized Trial. JAMA 2003;290:1729-1738.
3. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
4. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
5. Fletcher SW, Colditz GA. Failure of estrogen plus progestin therapy for prevention [Editorial]. JAMA 2002;288:366-368.
6. North American Menopause Society. Amended report from the NAMS Advisory Panel on postmenopausal hormone therapy. Menopause 2003;10:6-12.
7. Center for Drug Evaluation and Research. (Updated) Questions and Answers for Estrogen and Estrogen With Progestin Therapies for Postmenopausal Women. US Food and Drug Administration; 2004.
8. Solomon CG, Dluhy RG. Rethinking postmenopausal hormone therapy. N Engl J Med 2003;348:579-580.
9. US Preventive Services Task Force. Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: recommendations and rationale. Ann Intern Med 2002;137:834-839.
10. Simon JA, Wysocki S, Brandman MS, et al. A comparison of therapy continuation rates of different hormone replacement agents: a 9-month retrospective, longitudinal analysis of pharmacy claims among new users. Menopause 2003;10:37-44.
11. Hersh AL, Stefanik ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291:47-53.
12. Ettinger B, Grady D, Tosteson ANA, et al. Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapy. Obstet Gynecol 2003;102:1225-1232.
13. Schneider DL, Barrett-Connor EL, Morton DJ. Timing of postmenopausal estrogen for optimal bone mineral density: the Rancho Bernardo study. JAMA 1997;277:543-547.
14. Nelson HD, Rizzo J, Harris E, et al. Osteoporosis and fractures in postmenopausal women using estrogen. Arch Intern Med 2002;162:2278-2284.
15. Tremollieres FA, Pouilles J-M, Ribot C. Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women. Osteoporos Int 2001;12:385-390.
16. Paganini-Hill A, Chao A, Ross RK, et al. Exercise and other factors in the prevention of hip fracture: the Leisure World study. Epidemiology 1991;2:16-25.
17. Michaelsson K, Baron JA, Farahmand BY, et al. Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group. BMJ 1998;316:1858-1863.
18. Weiss NS, Ure CL, Ballard JH, et al. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 1980;303:1195-1198.
19. Yates J, Barrett-Connor E, Barlas S, et al. Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment. Obstet Gynecol 2004;103:440-446.
20. NIH Consensus Development Panel. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-795.
21. Garnero P, Sornay-Rendu E, Chapuy M-C, et al. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 1996;11:337-349.
22. Garnero P, Hausherr E, Chapuy M-C, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study. J Bone Miner Res 1996;11:1531-1538.
23. Greenspan SL, Emkey RD, Bone HG, et al. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;137:875-883.
24. Guyatt GH. Evidence-based management of patients with osteoporosis. J Clin Densitom 1998;1:395-402.
25. Sackett DL. Rules of evidence and clinical recommendations. Can J Cardiol 1993;9:487-489.
26. Clarke M, Oxman AD. Cochrane Reviewers' Handbook 4.2.0 (updated March 2003). 2003.
27. Wasnich RD, Bagger YZ, Hosking D, et al. Changes in bone density and turnover after alendronate or estrogen withdrawal. Menopause 2004;11:622-630.
28. Saarto T, Vehmanen L, Eiomaa I, et al. The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer. Br J Cancer 2001;84:1047-1051.
29. Warming L, Christoffersen C, Riis BJ, et al. Adverse effects of a SERM (levormeloxifene): safety parameters and bone mineral density 12 months after treatment withdrawal. Maturitas 2003;44:189-199.
30. Neele SJM, Evertz R, de Valk-de Roo G, et al. Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone 2002;30:599-603.
31. Gallagher JC, Rapuri PB, Haynatzki G, et al. Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. J Clin Endocrinol Metab 2002;87:4914-4923.
32. Greendale GA, Espeland MA, Slone S, et al. Bone mass response to discontinuation of long-term hormone replacement therapy. Arch Intern Med 2002;162:665-672.
33. Ascott-Evans BH, Guanabens N, Kivinen S, et al. Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy. Arch Intern Med 2003;163:789-794.
34. Christiansen C, Christensen MS, Transbol I. Bone mass in postmenopausal women after withdrawal of oestrogen/ gestagen replacement therapy. Lancet 1981;1:459-461.
35. Lindsay R, MacLean A, Kraszewski A, et al. Bone response to termination of oestrogen treatment. Lancet 1978;1:1325-1327.
36. Erdtsieck RJ, Pols HAP, Algra D, et al. Bone mineral density in healthy Dutch women: spine and hip measurements using dualenergy x-ray absorptiometry. Neth J Med 1994;45:198-205.
37. Ravn P, Bidstrup M, Wasnich RD, et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the Early Postmenopausal Intervention Cohort Study. Ann Intern Med 1999;131:935-942.
38. Bone HG, Greenspan SL, McKeever C, et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab 2000;85:720-726.
39. Barrett-Connor E, Espeland MA, Greendale GA, et al. Postmenopausal hormone use following a 3-year randomized clinical trial. J Womens Health Gend Based Med 2000;9:633-643.
40. Kanis JA, Oden A, Johnell O, et al. Uncertain future of trials in osteoporosis. Osteoporos Int 2002;13:443-449.
41. Cranney A, Guyatt G, Griffith L, et al. IX. Summary of metaanalysis of therapies for postmenopausal osteoporosis. Endoer Rev 2002;23:570-578.
42. Khosla S. Surrogates for fracture endpoints in clinical trials. J Bone Miner Res 2003;18:1146-1149.
43. US Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, Office of the Surgeon General; 2004.
44. National Osteoporosis Foundation. Osteoporosis: review of the evidence for prevention, diagnosis, and treatment and cost-effectiveness analysis. Osteoporos Int 1998;8(suppl 4):S1-S88.